Moreover, the enormous potential bias introduced by having nonblinded evaluators perform all the pre-ECT, post-ECT, and 6-month follow-up clinical and cognitive testing, while collecting all the ECT treatment data during each treatment, is simply immeasurable. Could there not have been a single evaluator at any of the 7 sites whose ratings were colored by a privately held belief that bilateral ECT could cause persistent cognitive deficits at 6 months?
One or two such flaws in a piece of research with such important ramifications would generally preclude acceptance of an article in a peer-reviewed journal, and it is therefore striking that the only methodological limitation of their study that the authors noted in their discussion was the fact that treatment differences were not randomized. This is especially puzzling because, in an earlier article based on the same community hospital patient sample, 3 the same authors observed that the ''doctor's choice'' remission rates obtained were only half as good as expected from the literature and attributed this in large part to contamination of the sample with substantial numbers of depressives with comorbid personality disorders and schizoaffective disorder. The authors laid the blame for the poor outcomes obtained squarely on the ''doctor's choice'' treatment providers, who routinely declared patients to be symptom-free after ECT when, in fact, they had significant residual symptoms, hardly a suitable setting from which to draw far-reaching conclusions about the cognitive effects of ECT.
An equally puzzling feature of the study was the inclusion for analysis of patients who had received sine-wave ECT, a method that has been recognized as obsolete since 1982, when it was first banned by the British government's National Health Service 4 ; other governments soon followed. Although Sackeim et al 2 did mention that 2 patients received sine-wave unilateral ECT, they nowhere revealed how many patients received sine-wave bilateral ECT, a group that certainly should have been excluded from the outset. Had they done so, they would have been able to conduct a straightforward analysis of the 6-month cognitive effects of ECT in a pure sample of pulse-bilateral patients (albeit without a suitable no-ECT control group), which is surely the group of primary interest. Thus, it remains unclear whether, without inclusion of the sine-wave patients, their bilateral sample was sufficiently large to provide the requisite power to show significant cognitive impairment at 6 months.
The authors might perhaps respond that their sophisticated statistical methods such as multivariate analyses of covariance allowed them to partial out all these potential confounds, but if such analyses were all that were required to correct the multiform undesirable effects of serious methodological flaws, why would so much money and time be spent each year to insure the conduct of planned, prospective, random-assignment, double-blind trials, which are the gold standard of all research? The answer is that such trialsVand only such trialsVare capable of providing the facts that are needed for a valid and reliable assessment of medical treatments.
